Statement by FDA Commissioner Scott Gottlieb, M.D., and Biologics Center Director Peter Marks, M.D., Ph.D. on FDA’s continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk, while progressing the agency’s commitment to help advance legitimate stem cell product development under existing agency regulations - FDA Press Releases

FDA statement on stem cell enforcement actions and agency activities to facilitate legitimate product development

from Food and Drug Administration--Press Releases https://ift.tt/2HX0s0C
via IFTTT